<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2589">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04479163</url>
  </required_header>
  <id_info>
    <org_study_id>FundacionINFANT-Plasma</org_study_id>
    <nct_id>NCT04479163</nct_id>
  </id_info>
  <brief_title>Prevention of Severe Covid-19 in Infected Elderly by Early Administration of Convalescent Plasma With High-titers of Antibody Against SARS-CoV2</brief_title>
  <official_title>Prevention of Severe Covid-19 in Infected Elderly by Early Administration of Convalescent Plasma With High-titers of Antibody Against SARS-CoV2.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion Infant</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundacion Infant</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Trial design. Randomized, double-blind, placebo-controlled trial in a catchment population of&#xD;
      2,020,860 age-appropriate subjects in the state of Buenos Aires and 235,000 in the city of&#xD;
      Buenos Aires.&#xD;
&#xD;
      Institutions. Hospitals San Juan de Dios, Simplemente Evita, Dr. Carlos Bocalandro, Evita&#xD;
      Pueblo, Sanatorio Antartida, Hospital Central de San Isidro, Clinica Olivos in the state of&#xD;
      Buenos Aires with 38 regional and town hospitals acting as referral centers, and Hospital&#xD;
      Militar Central, Sanatorio de Los Arcos, Hospital Universitario CEMIC, Sanatorio Sagrado&#xD;
      Corazon, Sanatorio Finochietto, Sanatorio Anchorena, Centro Gallego, and in the city of&#xD;
      Buenos Aires in Argentina.&#xD;
&#xD;
      Study population. Subjects &gt;= 75 years of age irrespective of presenting comorbidities or&#xD;
      between 65-74 years of age with at least one comorbidity (hypertension, diabetes, obesity,&#xD;
      chronic renal failure, and COPD) who experience the following signs and symptoms for less&#xD;
      than 48 hours at the time of screening for SARS CoV2 by RT-PCR: (a) a temperature &gt;=37.5°C&#xD;
      and/or unexplained sweating and/or chills and (b) at least one of the following: dry cough,&#xD;
      dyspnea, fatigue, myalgia, anorexia, sore throat, loss of taste and/or smell, rhinorrhea.&#xD;
      Subjects consenting to screening will be tested by&#xD;
      reverse-transcriptase-polymerase-chain-reaction (RT-PCR) for SARS-CoV-2 in a nasopharyngeal&#xD;
      and an oropharyngeal swab and invited to participate when RNA for the virus is detected.&#xD;
&#xD;
      Intervention. Eligible, consenting patients will be randomized using an electronic system to&#xD;
      receive 250 ml of convalescent plasma with an IgG titer against SARS-CoV2 spike (S) protein&#xD;
      &gt;1:1,000 (COVIDAR IgG, Insituto Leloir, Argentina) or placebo (normal saline 0.9%)&#xD;
      administered in a 1:1 ratio. Both treatment and placebo will be concealed using dark bags and&#xD;
      tape to cover the infusion line. Treatment will be administered &lt;72 hours from initiation of&#xD;
      symptoms. Subjects will be monitored for 12 hours after treatment for adverse events.&#xD;
&#xD;
      Clinical and laboratory monitoring. All participating subjects will be admitted to the&#xD;
      hospital upon enrollment. Twenty-four hours after completing the infusion, a sample of venous&#xD;
      blood (5 ml) will be obtained from all participants to measure anti-S IgG SARS-CoV2 in serum&#xD;
      (COVIDAR IgG, Leloir) and preserved at -20°C until completion of the study. Patient evolution&#xD;
      will be assessed daily by study physicians during hospitalization until day 25 and/or at home&#xD;
      until day 15, in the event of earlier discharge from the hospital. Study physicians will use&#xD;
      predesigned questionnaires to collect clinical information. An Independent Data Safety&#xD;
      Monitoring Board (DSMB) will supervise participating subjects during the study.&#xD;
&#xD;
      Endpoints. The primary endpoint of the trial is development of severe respiratory disease&#xD;
      defined as a respiratory rate (RR)&gt;30 and/or an O2 sat&lt;93% when breathing room air determined&#xD;
      using a predefined protocol. Three other clinical endpoints include (a) life threatening&#xD;
      respiratory disease, defined as need for 100% oxygen supplementation and/or non-invasive or&#xD;
      invasive ventilation and/or admission to intensive care; (b) critical systemic illness,&#xD;
      defined as respiratory failure (PaO2/FiO2 ≤ 200 mm Hg) and/or shock and/or multiorganic&#xD;
      distress syndrome; and (c) death.&#xD;
&#xD;
      Statistical analysis. The study is designed to have one interim analysis when the outcome&#xD;
      results for 50% of the subjects is obtained. The minimally clinically important difference&#xD;
      was set at a 40% relative reduction for an expected outcome rate of 50% in the control group&#xD;
      reduced to 30% in the intervention group. A total sample size of 210 subjects (105 per trial&#xD;
      arm) was estimated to have 80% power at a significance level (alpha) of 0.05 using a&#xD;
      two-sided z-test with continuity correction.&#xD;
&#xD;
      Ethical considerations. The trial has been approved by the institutional review boards of&#xD;
      participating institutions and the Central Ethics Committee of the state of Buenos Aires. The&#xD;
      study will be conducted in accordance with the principles of the Declaration of Helsinki and&#xD;
      the Good Clinical Practice guidelines of the International Conference on Harmonization.&#xD;
      Written informed consent will be obtained from all patients for screening and enrollment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 4, 2020</start_date>
  <completion_date type="Actual">October 25, 2020</completion_date>
  <primary_completion_date type="Actual">October 25, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Development of severe respiratory disease defined as a respiratory rate (RR)&gt;30 and/or an O2 sat&lt;93%</measure>
    <time_frame>From 12 hours post infusion to day 15 post infusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Life threatening respiratory disease</measure>
    <time_frame>From 12 hours post infusion to day 25 post infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Critical systemic illness, defined as respiratory failure</measure>
    <time_frame>From 12 hours post infusion to day 25 post infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>From 12 hours post infusion to day 25 post infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combination of secondary outcomes #2 (Life threatening respiratory disease) and/or #3 (Critical systemic illness, defined as respiratory failure) and//or #4 (death)</measure>
    <time_frame>From 12 hours post infusion to day 25 post infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of oxygen support requirement in patients with covid-19 due to saturation in ambient air &lt;93%.</measure>
    <time_frame>From 12 hours post infusion to day 25 post infusion</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">165</enrollment>
  <condition>COVID</condition>
  <arm_group>
    <arm_group_label>Plasma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Convalescent plasma with an IgG titer against SARS-CoV2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal Saline 0.9%</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Convalescent Plasma</intervention_name>
    <description>250 ml Convalescent plasma with an IgG titer against SARS CoV2</description>
    <arm_group_label>Plasma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal Saline 0.9%</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Age ≥ 75 or age 65-74 with at least 1 of the following comorbidities: arterial&#xD;
        hypertension, diabetes, obesity, chronic obstructive pulmonary disease, heart disease,&#xD;
        chronic kidney disease&#xD;
&#xD;
          -  Last 48 hours: (A)Axillary temperature ≥ 37.5oC or febrile equivalent, combined with&#xD;
             (a) dry cough and/or (b) breathing difficulty and/or (c) odinophagia and/or (d)&#xD;
             anosmia/dysgeusia and/or (e) any of the following symptoms: fatigue, anorexia,&#xD;
             myalgias or rhinorrhea.&#xD;
&#xD;
          -  Confirmed diagnosis SARS-Cov2 by RT-PCR&#xD;
&#xD;
          -  Give Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe respiratory disease&#xD;
&#xD;
          -  Cardiac insufficiency,&#xD;
&#xD;
          -  Chronic renal failure,&#xD;
&#xD;
          -  Primary hypogammaglobulinemias,&#xD;
&#xD;
          -  Myelodysplastic syndromes,&#xD;
&#xD;
          -  Chronic linfoproliferative syndromes,&#xD;
&#xD;
          -  Monoclonal gammapathies,&#xD;
&#xD;
          -  Known hypersensitibility,&#xD;
&#xD;
          -  Active cancer,&#xD;
&#xD;
          -  HIV, HBV or HCV infection,&#xD;
&#xD;
          -  Chronic administration of immunosuppressants,&#xD;
&#xD;
          -  Body transplant history,&#xD;
&#xD;
          -  Chronic liver disease, Chronic lung disease with oxygen requirement.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fernando P Polack, MD</last_name>
    <role>Study Director</role>
    <affiliation>Fundacion Infant</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Militar Central</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>1426</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CEMIC</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigacion Clinica OSECAC</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Gallego de Buenos Aires</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanatorio Anchorena</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanatorio de Los Arcos</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital &quot;Simplemente Evita&quot;</name>
      <address>
        <city>González Catán</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Especializado de Agudos y Crónicos &quot;San Juan de Dios&quot;</name>
      <address>
        <city>La Plata</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Olivos</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Central de San Isidro</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Agudos &quot;Dr. Carlos Bocalandro&quot;</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>June 29, 2020</study_first_submitted>
  <study_first_submitted_qc>July 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2020</study_first_posted>
  <last_update_submitted>December 19, 2020</last_update_submitted>
  <last_update_submitted_qc>December 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

